A Meta-Analysis of the Association Between SIRT1 Expression with Tumors Drug-Resistance

Author(s): Xiaolu Fang, Yandong Ci, Zhe Sun, Hong Yu

Objective: SIRT1(silent information regulator 1), a member of the highly conserved sirtuins family, has been reported to be abnormally expressed in a wide variety of cancers. Numerous studies have reported the association between SIRT1 and cancer drug resistance, but the data of different reports remains controversial. To further evaluate the role of SIRT1 in tumor resistance, a meta-analysis based on published studies was conducted. Methods: Relevant articles before September 2018 on SIRT1 and Drug-resistant tumor were searched via PubMed, Embase, Web Of Science (WOS). The studies were chosen for the meta-analysis based on requisite criteria. The relation was analyzed using RevMan 5.3 software. Odds ratios (OR) and their 95% corresponding confidence intervals (CI) were pooled to estimate the effect of specific associations. Results: A total of 14 eligible studies containing 790 patients were included, in which most of the patients overexpressed SIRT1. The results showed that SIRT1 overexpression significantly correlated with the risk of cancer drug resistance (OR=7.99, 95% CI: 5.70–11.21, P<0.00001). Conclusions: The overall data of the shown meta-analysis suggested that the expression of SIRT1 is correlated with cancer risk cancer drug resistance.

SIRT1, Cancer, Drug Resistance, Clinicopathological Characteristics, Meta-Analysis

1. Ryerson, A.B., et al., Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer, 2016. 122(9): p. 1312-37.
2. Donin, N., et al., Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer, 2016. 122(19): p. 3075-86.
3. Yao, C.J., et al., Activation of p53/miR-34a tumor suppressor network by Chinese herbal recipe JP-1 in human lung cancer cells. Cancer Research, 2015. 75(15).
4. Zeng, Y., Advances in mechanism and treatment strategy of cancer. Cellular and Molecular Biology, 2018. 64(6): p. 1-3.
5. Wu, Q.B., et al., Role of microRNAs in the resistance of colorectal cancer to chemoradiotherapy (Review). Molecular and Clinical Oncology, 2018. 8(4): p. 523-527.
6. Wang, Z. and W.Y. Chen, Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes and Cancer, 2013. 4(3-4): p. 82-90.
7. Rosano, C., Sirtuins as drug targets. Current Drug Targets, 2013. 14(6): p. 621.
8. Liu, T., P.Y. Liu, and G.M. Marshall, The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer. Cancer Research, 2009. 69(5): p. 1702-1705.
9. Shen, D.W., et al., Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacological Reviews, 2012. 64(3): p. 706-721.
10. Zhang, T., et al., SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. PLoS ONE, 2013. 8(11).
11. Shin, D.H., Y.-J. Choi, and J.-W. Park, SIRT1 and AMPK Mediate Hypoxia-Induced Resistance of Non-Small Cell Lung Cancers to Cisplatin and Doxorubicin. Cancer Research, 2014. 74(1): p. 298-308.
12. Chen, H.-C., et al., SIRT1 Promotes Tumorigenesis and Resistance to Chemotherapy in Hepatocellular Carcinoma and its Expression Predicts Poor Prognosis. Annals of Surgical Oncology, 2012. 19(6): p. 2011-2019.
13. Choi, H.-K., et al., SIRT1-Mediated FoxO1 Deacetylation Is Essential for Multidrug Resistance-Associated Protein 2 Expression in Tamoxifen-Resistant Breast Cancer Cells. Molecular Pharmaceutics, 2013. 10(7): p. 2517-2527.
14. Oon, C.E., et al., SIRT1 inhibition in pancreatic cancer models: Contrasting effects in vitro and in vivo. European Journal of Pharmacology, 2015. 757: p. 59-67.
15. Zhang, L., X. Wang, and P. Chen, MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells. BMC Cancer, 2013. 13.
16. Shuang, T., et al., Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC). Medical Oncology, 2015. 32(12).
17. Cao, B., Q. Shi, and W. Wang, Higher expression of SIRT1 induced resistance of esophageal squamous cell carcinoma cells to cisplatin. Journal of Thoracic Disease, 2015. 7(4): p. 711-719.
18. Wang, M., et al., Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell death & disease, 2018. 9(12): p. 1149.
19. Asaka, R., et al., Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target. Laboratory Investigation, 2015. 95(12): p. 1363-1373.
20. Lin, M.-H., et al., Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1). Molecules, 2016. 21(7).
21. Hisahara, S., et al., Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci U S A, 2008. 105(40): p. 15599-604.
22. Wilking, M.J. and N. Ahmad, The Role of SIRT1 in Cancer: The Saga Continues. American Journal of Pathology, 2015. 185(1): p. 26-28.
23. Zeng, L., et al., Silent information regulator, Sirtuin 1, and age-related diseases. Geriatrics and Gerontology International, 2009. 9(1): p. 7-15.
24. Kelly, G.S., A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: Part 2. Alternative Medicine Review, 2010. 15(4): p. 313-328.
25. Horio, Y., et al., Cellular and molecular effects of sirtuins in health and disease. Clinical Science, 2011. 121(5): p. 191-203.
26. Xiong, H., et al., LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene, 2017. 36(25): p. 3528-3540.
27. Ling, S., et al., USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Molecular Oncology, 2017. 11(6): p. 682-695.